Table 2

Multivariable analysis for predictors of major clinical response to first cycle rituximab

No response/partial response n=59Major clinical response n=58Univariable OR (95% CI),
p value
(with multiple imputation)
Multivariable OR (95% CI),
p value
(with multiple imputation)
Age, mean (SD) years43 (17)37 (14) 0.97 (0.95 to 0.99), p=0.031 per year 0.97 (0.94 to 1.00), p=0.045
White, N (%)43 (73)37 (64)1.53 (0.70 to 3.34), p=0.2920.92 (0.34 to 2.47), p=0.870
Anti-dsDNA titres, mean (SD) IU/mL147 (230)142 (230)1.00 (0.99 to 1.00), p=0.879 per unit1.00 (0.99 to 1.00), p=0.632
Anti-ENA positivity, N (%)40 (68)38 (66)0.91 (0.42 to 1.99), p=0.8120.90 (0.37 to 2.22), p=0.821
Low C3 and/or C4 titres, N (%)25 (42)24 (41)0.97 (0.46 to 2.04), p=0.9371.14 (0.41 to 3.13), p=0.801
ESR, mean (SD) mm/hour*40 (32)41 (36)1.00 (0.99 to 1.01), p=0.827 per unit-
Concomitant S, N (%)†41 (69)35 (60)0.67 (0.31 to 1.43), p=0.3010.43 (0.17 to 1.09), p=0.075
Daily prednisolone dose, mean (SD) mg13 (11)16 (14)1.02 (0.99 to 1.05), p=0.207 per mg1.00 (0.97 to 1.04), p=0.713
Total BILAG score, mean (IQR)21 (8)24 (13)1.03 (0.99 to 1.07), p=0.093 per point1.02 (0.97 to 1.07), p=0.371
Total B-cell counts, mean (IQR)‡101 (95)138 (150)1.00 (1.00 to 1.01), p=0.161 per unit1.00 (1.00 to 1.01), p=0.137
B-cell depletion at 6 weeks postrituximab, N (%)29 (49)39 (68)2.10 (0.95 to 4.62), p=0.065 3.22 (1.24 to 8.33), p=0.016
  • *As high collinearity was observed between ESR and total B-cell counts, only the latter was included in the multivariable analysis.

  • †Concomitant immunosuppressant was defined as either using methotrexate, azathioprine, mycophenolate mofetil and/or other disease modifying anti-rheumatic drugs but excluded anti-malarials

  • ‡count x 109 cells/L) for each subset multiplied by 1000 prior to analysis.

  • BILAG, British Isles Lupus Assessment Group; C3/C4, complement 3 or 4; dsDNA, double-stranded DNA; ENA, extract nuclear antigen; ESR, erythrocyte sedimentation rate; IS, immunosuppressant.